StockData
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1

QuidelOrtho Corp

Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)

Close on Oct 19, 2026

Market cap
$871.51M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 28, 2026
Aug 6, 2026After market close$631.00M$-1.36$0.13
Q1 FY2026
Ended Mar 29, 2026
May 5, 2026After market close$620.00M$-1.35$-0.04
Q4 FY2025
Ended Dec 28, 2025
Feb 11, 2026After market close$724.00M$-1.92$0.46
Q3 FY2025
Ended Sep 28, 2025
Nov 5, 2025After market close$700.00M$-10.78$0.80
Q2 FY2025
Ended Jun 29, 2025
Aug 5, 2025After market close$614.00M$-3.77$0.12
Q1 FY2025
Ended Mar 30, 2025
May 7, 2025After market close$693.00M$-0.19$0.74
Q4 FY2024
Ended Dec 29, 2024
Feb 12, 2025After market close$708.00M$-2.28$0.63
Q3 FY2024
Ended Sep 29, 2024
Nov 7, 2024After market close$727.00M$-0.30$0.85
Q2 FY2024
Ended Jun 30, 2024
Jul 31, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 13, 2024After market close–––

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDAnon-GAAPFull-year 2026$540.00M to $560.00MNew
Adjusted diluted EPSnon-GAAPFull-year 2026$0.65 to $0.90New
Adjusted EBITDA marginnon-GAAPFull-year 202621% to 22%New
Total revenues (reported)Full-year 2026$2.52B to $2.60BNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements QuidelOrtho filed with the SEC